Dose Insider / Glossary / Visceral adipose tissue

Visceral adipose tissueThe fat around the organs, and what GLP-1 drugs do to it

Updated November 20, 2026 · 3 min read · Look 2025 and Wilding 2021 DXA studies; SURPASS-3 MRI; Neeland 2019

Visceral adipose tissue, or VAT, is the fat inside the abdomen, around the organs, as opposed to the fat under the skin.1 A 2019 position statement from the International Atherosclerosis Society and an international working group on visceral obesity describes visceral adiposity and ectopic fat as emerging risk factors for type 2 diabetes, atherosclerosis and cardiovascular disease.2 In the body scans of the GLP-1 trials, visceral fat fell faster than body fat as a whole.

40.1%Visceral fat, Zepbound, 72 weeks, fat lost, by body scan
Fat lost, by body scan% fall from the start, trial averagesVISCERAL FATZepbound, 72 weeks40.1%Wegovy, 68 weeks27.4%Placebo, Zepbound trial7.3%ALL BODY FATZepbound, 72 weeks33.9%Wegovy, 68 weeks19.3%Placebo, Zepbound trial8.2%Fat lost, by body scan% fall from the start, trial averagesVISCERAL FATZepbound, 72 weeks40.1%Wegovy, 68 weeks27.4%Placebo, Zepbound trial7.3%ALL BODY FATZepbound, 72 weeks33.9%Wegovy, 68 weeks19.3%Placebo, Zepbound trial8.2%

Visceral fat fell faster than body fat as a whole.

On this page

How it is measured

The scale cannot tell visceral fat from any other weight. Trials measure it with DXA, a weak X-ray beam passed over the whole body that sorts each part into fat, bone mineral and lean tissue, or with MRI.1,3 The 2019 statement covers how these fats are measured, how they contribute to disease, how they respond to treatment, and lessons from a public health programme that targeted them. It notes that simple, clinically usable tools to follow them over time are still needed. It also calls for public health messages to focus on these fats as well as on body weight.2

What the scans showed

The two studies were separate, with different drugs, lengths and people, so the figures are not a head-to-head comparison. The same scans showed lean tissue falling too, by 10.9% on tirzepatide and 9.7% on semaglutide. Our page on muscle loss on a GLP-1 shows the full split of what the lost weight was made of.

Liver fat in people with diabetes

SURPASS-3 MRI measured fat by MRI in 296 adults with type 2 diabetes, comparing weekly tirzepatide with daily insulin degludec for 52 weeks. The participants had an HbA1c of 7.0 to 10.5%, a BMI of at least 25, had never used insulin, took metformin alone or with an SGLT2 inhibitor, and had a fatty liver index of at least 60. The study was open-label, ran at 45 centres in eight countries and was funded by Eli Lilly. MRI separated the fat inside the abdomen from abdominal subcutaneous adipose tissue, the fat under the skin. Liver fat started at an average of 15.71% of the liver. It fell by 8.09 percentage points on tirzepatide 10 or 15 mg, against 3.38 on insulin degludec. Tirzepatide also reduced the volumes of visceral fat and of abdominal fat under the skin. On tirzepatide, a larger fall in liver fat went with larger falls in visceral fat, in fat under the skin and in body weight.3

What it means in practice

For most people, a DXA or MRI scan is not part of treatment, and the trials scanned only a subset of their participants: 160 in SURMOUNT-1 and 140 in STEP 1. The waist is a simple measure the Zepbound study also reported: an average fall of 18.1 cm against 3.4 cm on placebo.1 A tape measure at the same spot each month shows a trend that the scale alone cannot.

Sources

  1. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025;27:2720-2729. doi:10.1111/dom.16275
  2. Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019;7:715-725. doi:10.1016/S2213-8587(19)30084-1
  3. Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393-406. doi:10.1016/S2213-8587(22)00070-5
  4. Wilding J, Batterham R, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc 2021;5(Suppl 1):A16-A17. PMC8089287

Related analyses

Log your waist each month next to your weight; it tracks the fat the scale cannot separate.

Open Dose Insider